Avanos Medical, Inc. (NYSE:AVNS) Shares Bought by Quadrature Capital Ltd

Quadrature Capital Ltd boosted its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 67.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,207 shares of the company’s stock after buying an additional 9,320 shares during the period. Quadrature Capital Ltd’s holdings in Avanos Medical were worth $521,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Alberta Investment Management Corp increased its holdings in shares of Avanos Medical by 16.6% in the fourth quarter. Alberta Investment Management Corp now owns 413,418 shares of the company’s stock valued at $9,273,000 after purchasing an additional 58,826 shares during the period. Kestrel Investment Management Corp purchased a new stake in shares of Avanos Medical in the fourth quarter valued at approximately $3,265,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Avanos Medical by 6.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 570,442 shares of the company’s stock valued at $11,534,000 after buying an additional 34,825 shares in the last quarter. Norges Bank purchased a new stake in shares of Avanos Medical in the fourth quarter valued at approximately $7,016,000. Finally, Foundry Partners LLC boosted its stake in shares of Avanos Medical by 74.6% in the fourth quarter. Foundry Partners LLC now owns 371,029 shares of the company’s stock valued at $8,322,000 after buying an additional 158,473 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Stock Up 0.6 %

AVNS opened at $19.56 on Monday. The business’s fifty day moving average is $19.49 and its two-hundred day moving average is $19.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28. The company has a market cap of $897.80 million, a price-to-earnings ratio of -14.71 and a beta of 0.98. Avanos Medical, Inc. has a one year low of $17.24 and a one year high of $26.56.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Thursday, May 2nd. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02). The firm had revenue of $166.10 million for the quarter, compared to analysts’ expectations of $162.90 million. Avanos Medical had a positive return on equity of 4.10% and a negative net margin of 9.15%. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 earnings per share. Analysts anticipate that Avanos Medical, Inc. will post 1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AVNS. StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th. JMP Securities restated a “market perform” rating on shares of Avanos Medical in a research note on Tuesday, May 7th.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.